Back to top


Dr. Gang Fu, Co-Founder and Chairman of the Board

Dr. Fu is the founder and current CEO of Baheal Pharmaceutical Group, a corporation focused on the innovation and integration of resources in the healthcare industry, engaged in consumer and pharmaceutical sales and marketing, digital health solutions, and pharmaceutical development. Baheal’s holding, Baheal Smart Tech, develops and offers healthcare solutions, and recently partnered with IBM Watson to bring healthcare AI technology to China. Dr. Fu’s other holdings include hospital data management, physician training service, and patient management systems.

Previously, Dr. Fu was the Marketing Vice President of Livzon (Pharmaceutical) Group. He was named the first “National Top Ten Pharmaceutical Industry Professional Managers” by the China Pharmaceutical Enterprise Managers Association in 2005 and twice the “Outstanding Chinese Enterprise IT Leader” by CECA National Information Evaluation Center. In addition, he serves as Executive Director of the Chinese Medical Doctors Association, Vice Chairman of the China Pharmaceutical Enterprise Management Association, and Vice Chairman of the China Association of Pharmaceutical Commerce. Dr. Fu is a graduate of Peking University Medical School and practiced at Beijing Railway General Hospital.

Ms. Emma Xu, Co-Founder and CEO

Ms. Xu began her pharmaceutical manufacturing career with the founding of the D-Cal® brand, China’s best-selling calcium and vitamin D products to support bone health. D-Cal® has retained success in the China market for over 20 years, registered and marketed as both prescription and over-the-counter products. Ms. Xu brings her expertise in pharmaceutical manufacturing and CFDA & FDA regulations. She is a proud supporter of Go Red for Women (by AHA) and the Osteoporosis Foundation.

Mr. Jifeng Lei, Board Member

Mr. Lei is the founder of Anbison Laboratories. Prior to forming Anbison, a China-based CRO, he had overseen technical operations at various multinational pharmaceutical companies, including GSK (Tianjin), Sanofi-Aventis (Hangzhou), and Xian-Janssen. Mr. Lei holds a master’s degree in chemical engineering and an executive MBA from the Asian Institute of Management.